go-v.orgcodex
Menu
Page tools

codex · Chemistry

Lilotomab

Diagram for Lilotomab
Lilotomab (formerly tetulomab, HH1) is a murine monoclonal antibody against CD37, a glycoprotein which is expressed on the surface of mature human B cells. It was generated at the Norwegian Radium Hospital. · image: Wikimedia Commons

Lilotomab (formerly tetulomab, HH1) is a murine monoclonal antibody against CD37, a glycoprotein which is expressed on the surface of mature human B cells. It was generated at the Norwegian Radium Hospital. As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA. This compound is called 177Lu-HH1 or lutetium (177Lu) lilotomab satetraxetan (trade name Betalutin). As of 2016, a phase 1/2 clinical trial in people with non-Hodgkin lymphoma was underway.

Wikipedia contributors, "Lilotomab", Wikipedia, revision 1173861988, retrieved 20 November 2026, source, CC BY-SA 4.0.

More Chemistry · Search the codex